Board of Directors


Nancy Stagliano, PhD

Independent Director

Don Frail, PhD

Independent Director

Alan Crane

Entrepreneur Partner, Polaris Partners
Chairman & Co-Founder, Pandion Therapeutics

Dan Becker, MD PhD

Principal, Access Biotechnology

Christopher Fuglesang, PhD, JD

Co-Founder and Managing Director, Boxer Capital

Carlo Rizzuto, PhD

Partner, Versant Ventures

Mitchell Mutz, PhD

Partner, Codon Capital

Jill Carroll

Partner, S.R. One

Rahul Kakkar, MD

Chief Executive Officer

Nancy Stagliano, PhD   Independent Director

Nancy Stagliano, Ph.D., is an accomplished serial biotechnology entrepreneur. As chief executive officer, Dr. Stagliano has successfully launched and/or exited three consecutive biotech companies: CytomX Therapeutics (CTMX), iPierian and, most recently, True North Therapeutics. As chief executive officer and co-founder of True North Therapeutics, Dr. Stagliano led the company to its recent acquisition by Bioverativ, Inc. for a total deal value of up to $825 million. Under her leadership, True North discovered and developed a first-in-class monoclonal antibody in the classical complement pathway TNT009, which received breakthrough therapy designation from the U.S. Food & Drug Administration for the orphan indication, Cold Agglutinin Disease.

Previously, Dr. Stagliano was chief executive officer of iPierian, Inc., which applied human iPSCs to model neurodegenerative diseases. The company and its lead antibody program against Tau for the treatment of progressive supranuclear palsy (PSP) and Alzheimer’s disease were acquired by Bristol-Myers Squibb in April of 2014 for a total deal value of $725 million; the antibody is currently in a Phase 2 trial in PSP led by Biogen. From 2008–2010, Dr. Stagliano was the chief executive officer and co-founder of CytomX Therapeutics and a lead inventor on the CytomX Probody platform. Before moving to California, Dr. Stagliano worked in Cambridge, Mass., where she had an eight-year tenure at Millennium Pharmaceuticals.

Dr. Stagliano received her bachelor of science degree in electrical engineering and master of science degree in biomedical engineering from Drexel University in Philadelphia. She obtained her doctor of philosophy degree in neuroscience from the University of Miami, Miller School of Medicine, in Miami.

Don Frail, PhD   Independent Director

Don Frail, PhD, is an accomplished drug hunter with more than 25 years of experience across therapeutic areas. He is current a Senior Vice President at Allergan, leading the R&D efforts across research, pre-clinical sciences, clinical pharmacology, and external science/partnering. Since joining Allergan in 2014, he has been involved in most internally developed and externally sourced programs. Prior to Allergan, he served in leadership positions at Astra-Zeneca, Pfizer, Pharmacia, Wyeth and Abbott Labs and has been involved in the entry of more than 25 compounds into development.

Alan Crane   Entrepreneur Partner, Polaris Partners
Chairman & Co-Founder, Pandion Therapeutics

Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies.

He has served as founder, chairman and/or CEO in building eight Polaris companies. Alan’s latest venture is Dyno Therapeutics, which he co-founded along with Harvard Professor George Church and scientist Eric Kelsic. The company is using insights from computer science and biology to design better viruses for delivery in the rapidly growing field of gene therapy. Prior to Dyno, Alan founded Pandion, where he currently serves as chairman of the board. Alan was also a founding investor in KSQ Therapeutics, the leading company using CRISPR to systematically discover and pursue the best therapeutic targets for disease intervention. The company has raised over $150M in under 3 years, including a crossover round. Alan’s portfolio companies have collectively been involved in 9 IPOs and M&A exits.

His current and past portfolio include: Momenta Pharmaceuticals, Visterra, Navitor Pharmaceuticals, Dyno Therapeutics, Pandion Therapeutics, KSQ Therapeutics, T2 Biosystems, Ocular Therapeutix, Sirtris Pharmaceuticals, Adnexus Therapeutics, Arsia Therapeutics, Seventh Sense Biosystems, Cerulean Pharma, and XTuit Pharmaceuticals. From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade®, which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.

Alan received Ernst & Young’s Entrepreneur of the Year award for New England and is an Always-On Venture Capital 100 recipient. His current and former non-profit positions include: selection committee for the Harvard Life Lab, expert-in-residence at the Harvard School of Engineering, board member of the Boston Children’s Hospital Trust, founder and vice chair of the Autism Consortium, and president of the board of Gann Academy.

Alan earned a BA in biology, summa cum laude, from Harvard College, an MA in cellular and developmental biology from Harvard Graduate School of Arts & Sciences and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.

Dan Becker, MD PhD   Principal, Access Biotechnology

Dan Becker is a physician-scientist and biopharma investor.

Dan joined Access Biotechnology in 2019.  Prior to Access, Dan was a Principal at New Leaf Venture Partners, where he played a key role in multiple private and public biopharma investments, and a Principal in the Health Care practice at the Boston Consulting Group, where he led projects across the health care sector with an emphasis on biopharma R&D.  Dan trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his M.D. and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan, and received his B.S. in Physiology from the University of Illinois at Urbana-Champaign.

Christopher Fuglesang, PhD, JD   Co-Founder and Managing Director, Boxer Capital

Christopher Fuglesang is Co-Founder and Managing Director of Boxer Capital, LLC. After joining Tavistock Group in 2005, Dr. Fuglesang helped scale Tavistock Group’s public healthcare investing activities with Boxer Capital. Dr. Fuglesang assists in managing the firm’s research team, deal structuring, and securities compliance.

Dr. Fuglesang is a Member of the Board of Directors of CiVi Biopharma, Inc. and serves as a Board Observer of Passage Bio, Poseida Therapeutics Inc., and Springworks Therapeutics, LLC.

Earlier in his career, Dr. Fuglesang supervised a variety of transactions, including mergers and acquisitions, joint ventures, and other strategic collaborations in the healthcare sector. Dr. Fuglesang brings with him years of experience in building and developing life science companies, previously founding and holding board and executive management positions at multiple biotechnology companies.

Dr. Fuglesang holds a Doctorate degree in Chemical Physics from the University of California, Los Angeles, a Juris Doctor degree from the Boston University School of Law, and Bachelor of Science degrees in Chemistry and Physics from the University of California, Los Angeles.

Carlo Rizzuto, PhD   Partner, Versant Ventures

Carlo Rizzuto is a Partner with Versant Ventures and focuses on biotech investing and company building.

Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising US and European clients in the pharmaceutical, payor and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup.

Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.

Mitchell Mutz, PhD   Partner, Codon Capital

Mitchell Mutz, PhD, is an accomplished biotech serial entrepreneur, venture investor, and inventor.  He is currently a partner at Codon Capital, a new venture fund focused on early stage investment opportunities in therapeutics and synthetic biology.

Prior to joining Codon, Mitchell was  the Senior Investment Director at the Roche Venture Fund, a $500M Swiss corporate venture fund which invests for financial return.  His portfolio included Enliven Therapeutics, Fabric Genomics, Good Therapeutics, Jasper Therapeutics, Kumquat Biosciences, lino Biotechnology, Pandion Therapeutics (NASDAQ:PAND), Purigen Biosystems, Stratos Genomics (acquired by Roche) and BlueLight Therapeutics.  He also collaborated on three new company spinouts from Roche which attracted over $50M in external venture investment.  Before that he served as a venture partner at Codon Capital.

Previously, Mitchell was a co-founder, president, chief scientific officer, and board member of Amplyx Pharmaceuticals, Inc., a biotherapeutics company and Stanford University spinout. Mitchell led the company’s R&D efforts, team building, as well as financing and in-licensing strategy and helped grow the company from early preclinical discovery to the clinical stage.  Amplyx has attracted over $140M in venture financing as well as over $11M in non-dilutive funding from the NIH.  Amplyx had a successful Phase 2 clinical trial readout in July 2020 and plans to commence Phase 3 studies in 2021.

Mitchell was also on the founding team and the Principal Scientist of Labcyte, a tools company that he helped grow from a garage-based start-up to profitability. Mitchell was responsible for discovering and and developing biotechnology applications for Labcyte’s novel acoustic drop ejection technology.  Labcyte employs over 250 people worldwide, attracted $85M in venture financing, and was acquired by Beckman Coulter Life Sciences for $308M.

Mitchell earned a Ph.D. in chemistry from the University of Rochester, a diploma in orchestral studies from the University of London, and a B.A. in chemistry with high honors from Oberlin College.  He also spent one year studying towards a PhD in the Department of Cellular and Developmental Biology at Harvard University.  Mitchell is also an inventor on 36 issued patents.

Jill Carroll   Partner, S.R. One

Ms. Jill Carroll is a Principal of SR One, and she joined SR One in 2011 with a background in biotech partnering and corporate development. Previously, she was Senior Director, Corporate Development at Dynavax Technologies (NASDAQ: DVAX) where she completed multiple pharma partnerships and substantial private and public financings. Jill was formerly a biopharmaceutical industry consultant at Clearview Projects and Mercer Management Consulting. She is a Director at Second Genome, Gotham Therapeutics, Arcellx, and Nkarta. She received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.

Rahul Kakkar, MD   Chief Executive Officer

Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience, spanning founding and building biotechnology companies, as well as working as a practicing physician. Most recently, he served as an executive at Corvidia Therapeutics where he was a founder, Chief Medical Officer and Chief Strategy Officer, guiding the company from seed stage through Series B and its lead asset through clinical proof of concept. Previously, he was Director for Emerging Innovations at AstraZeneca, responsible for preclinical through Phase 2 clinical studies both for compounds within the AstraZeneca pipeline and in support of compound out-licensing efforts. Dr. Kakkar has also served as an advisor to life sciences venture firms. He continues to practice medicine as Associate Physician at Brigham and Woman’s Hospital and is a Lecturer in Medicine at Harvard Medical School. Dr. Kakkar is dual-trained via the American Board of Internal Medicine Fast Track program in molecular biology and clinical cardiology. He received his BA from Tufts University and MD from the Tufts School of Medicine where he was a junior inductee of the Alpha Omega Alpha society. He is a fellow of the American College of Cardiology.

Back to Top